Today in the face of illness, millions of people are confronted with medical uncertainty. As patients and their physicians seek accurate diagnosis of their condition, precision diagnostics are playing important new roles in medicine, and are helping to inspire the growing presence of targeted treatments that define precision medicine today.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a leader in precision medicine with products designed to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care.
The Company focuses on the development and commercialization of innovative precision diagnostic agents and therapeutics that can and will make a difference for individuals – and families, physicians and care givers – touched by devastating conditions like cancer, autoimmune diseases, dementia and movement disorders. For patients and physicians, we aspire to provide innovative medical imaging agents and therapies to improve patient care for serious diseases. For investors, we aim to deliver superior growth through our focus on globally commercializing Lymphoseek®, developing our innovative Manocept™ platform and driving efficient business processes. For our employees, we provide a culture that focuses on the direct contributions our efforts make for the patients we serve and an innovative development environment for new breakthrough products.
Navidea’s products and pipeline include:
Lymphoseek®,(technetium Tc 99m tilmanocept) Injection a radiopharmaceutical agent for lymphatic mapping or sentinel lymph node biopsy for patients with several different types of solid tumor cancers. On March 13, 2013, the US FDA approved Lymphoseek® (technetium Tc 99m tilmanocept) injection. Following two supplemental NDA approvals in June 2014 and October 2014, Lymphoseek is now indicated for:
- Lymphatic mapping to locate lymph nodes in patients with solid tumors for which this procedure is a component of surgical management
- Guiding Sentinel Lymph Node Biopsy (SLNB) in patients with clinically node negative squamous cell carcinoma (SCC) of the oral cavity, breast cancer or melanoma.
In November 2014, Lymphoseek received European approval for Sentinel Lymph Node Detection in melanoma, breast and oral cavity head and neck cancers.
NAV4694 a powerful, second-generation PET imaging agent in Phase 3 development which may aid the differential diagnosis of mild cognitive impairment and dementia, including Alzheimer's disease, allowing patients to seek earlier treatment options.
The Manocept™ CD206 Targeting Platform for diagnostic and therapeutic applications focused on CD206-targeting of macrophages across a range of potential disorders including rheumatoid arthritis, Kaposi’s sarcoma, Crohn’s disease, cancer, tuberculosis, vulnerable plaque and others.
Navidea has more than 50 employees worldwide with headquarters in Dublin, Ohio.